Combination of α-blocker and 5α-reductase inhibitor for treatment of benign prostatic hyperplasia
Clinical and Investigative Medicine Nov 06, 2017
Kang D, et al. - The effectiveness of a α-blocker monotherapy alone with a combination of α-blocker plus 5α-reductase in the treatment of benign prostatic hyperplasia (BPH) is compared in this study. These outcomes show that combined α-blocker plus 5α-reductase therapy is more beneficial in treating benign prostatic hyperplasia in contrast to α-blocker monotherapy.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
